New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
06:33 EDTONCYOncolytics Biotech announces positive data from Resolysin clinical trial
Oncolytics Biotech announced that an abstract detailing early results from translational study looking at the intravenous administration of REOLYSIN to patients with primary or metastatic brain tumors is now available on the ASCO Annual Meeting abstract website. The conference is being held from May 30th to June 3rd Chicago, Illinois. The abstract, titled "Oncolytic wild-type reovirus infection in brain tumors following intravenous administration in patients," contends that intravenous delivery to brain tumors would be easier, cheaper and more acceptable to patients than intralesional administration.
News For ONCY From The Last 14 Days
Check below for free stories on ONCY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
07:38 EDTONCYOncolytics Biotech price target lowered to $3 from $5 at RBC Capital
Subscribe for More Information
September 17, 2014
10:00 EDTONCYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:10 EDTONCYOncolytics Biotech downgraded to Hold from Buy at Stifel
Stifel downgraded Oncolytics Biotech to Hold citing disappointing topline results from its Phase II pancreatic cancer study.
September 16, 2014
17:09 EDTONCYOncolytics Biotech announces patient data from phase 2 study with REOLYSIN
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use